Exelixis, Inc.
NASDAQ:EXELBiotechnology
+$0.34 today
- Market cap
- $17.17B
- Beta
- 0.43
- P/E (TTM)
- 16.3
- EPS (TTM)
- $3.23
Volume 1.82M
Average 2.55M
EXEL Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Exelixis, Inc.NASDAQ: EXEL
Other Working Capital · Q2 FY2026 · quarter ended Jul 2026
Other working capital turns positive
Q2 FY2026 other working capital was $31.2M, compared with -$108.67M a year earlier. Trailing-twelve-month other working capital was $45.77M. Over 3 fiscal years it compounded at +13.0% a year.
Context
- Other working capital amounted to 5.7% of revenue in FY2025, up 4.3 pp from a year earlier.
- Other working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other working capital holds near $31.2M or moves back toward the trailing-twelve-month quarterly average of $11.44M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (131.87M) USD
- Year-over-year change
- -526.4%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | (131.87M) | -526.4% |
| FY2024 | 2025-01-03 | 30.93M | +208.6% |
| FY2023 | 2023-12-31 | (28.48M) | +68.8% |
| FY2022 | 2022-12-31 | (91.32M) | -320.4% |
| FY2021 | 2021-12-31 | 41.43M | — |
Other Working Capital vs competitors
How EXEL compares with its peers on the latest reported figures
- EXEL's LTM Jul 2026 other working capital of $45.77M is the 4th largest of the 8 companies compared; the peer median is $29.04M.
- Its year-over-year change of +154.4% is the 2nd highest of 7, against a peer median of -106.0%.
- Other working capital amounts to 1.9% of revenue for EXEL, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.95B | +931.3% | +84.9% | 4.7% | |
| LTM Jun 2026 | $55.89M | +107.2% | — | — | |
| LTM Jun 2026 | $48.02M | -80.7% | — | 0.8% | |
| LTM Jul 2026 | $45.77M | +154.4% | +13.0% | 1.9% | |
| LTM Jun 2025 | $40.15M | -258.2% | — | 6.7% | |
| LTM Jun 2026 | $31.97M | — | — | 0.8% | |
| LTM Mar 2026 | $29.04M | -201.9% | — | 13.4% | |
| LTM Mar 2026 | $325K | -131.2% | +10.5% | 0.1% | |
| Peer median (excluding EXEL) | $29.04M | -106.0% | +47.7% | 2.8% | |
Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | 231.06M | 182.28M | 207.77M | 521.27M | 782.57M |
| Depreciation & Amortization | 13.63M | 20.88M | 25.72M | 28.8M | 29.06M |
| Deferred Income Tax | 46.53M | (60.36M) | (133.21M) | (59.46M) | 126.24M |
| Stock-Based Compensation | 119.82M | 107.57M | 106.35M | 93.84M | 112.98M |
| Change in Working Capital | (39.01M) | (12.8M) | (13.97M) | (13.45M) | (191.2M) |
| Accounts Receivables | (122.32M) | 66.85M | (22.62M) | (27.95M) | (21.4M) |
| Inventory | (13.21M) | (11.68M) | (12.98M) | 5.45M | 12.23M |
| Accounts Payables | 55.09M | 23.36M | 50.11M | (21.89M) | (50.15M) |
| Other Working Capital | 41.43M | (91.32M) | (28.48M) | 30.93M | (131.87M) |
| Other Non-Cash Items | 28.78M | 125.04M | 140.68M | 128.98M | 24.62M |
| Operating Cash Flow | 400.8M | 362.61M | 333.32M | 699.97M | 884.27M |
| Capital Expenditures | (64.23M) | (138.46M) | (162.97M) | (66.19M) | (39.93M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (1.36B) | (1.45B) | (902.47M) | (927.91M) | (632.5M) |
| Sales of Investments | 1.38B | 1.06B | 1.04B | 877.31M | 1.02B |
| Other Investing Activities | (10M) | (110.75M) | (122.5M) | (37.75M) | (31.5M) |
| Investing Cash Flow | (42.88M) | (524.41M) | (26.96M) | (116.78M) | 350.44M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 23.89M | 33.45M | 61.85M | 49.14M |
| Common Stock Repurchased | 0 | 0 | (550.38M) | (652.03M) | (947.51M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (14.8M) | (23.3M) | (29.12M) | (38.63M) | (71.22M) |
| Financing Cash Flow | (14.8M) | 586K | (546.05M) | (628.81M) | (969.59M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 343.12M | (161.21M) | (239.68M) | (45.62M) | 265.11M |
| Free Cash Flow | 336.58M | 224.16M | 170.36M | 633.79M | 844.34M |
Exelixis, Inc.
NASDAQ:EXEL
Intrinsic Alpha fair value
Locked
Current Price
$68.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.